US 7,588,767 B2
	Microorganisms for therapy
Aladar A. Szalay, Highland, Calif. (US); Tatyana Timiryasova, San Diego, Calif. (US); Yong A. Yu, San Diego, Calif. (US); and Qian Zhang, San Diego, Calif. (US)
Assigned to Genelux Corporation, San Diego, Calif. (US)
Filed on Jun. 18, 2004, as Appl. No. 10/872,156.
Claims priority of application No. 03013826 (EP), filed on Jun. 18, 2003; application No. 03018478 (EP), filed on Aug. 14, 2003; and application No. 03024283 (EP), filed on Oct. 22, 2003.
Prior Publication US 2005/0031643 A1, Feb. 10, 2005
Int. Cl. A01N 63/00 (2006.01); A61K 39/12 (2006.01); A61K 39/275 (2006.01); A61K 39/00 (2006.01); G01N 33/574 (2006.01); A61K 39/145 (2006.01)

U.S. Cl. 424—199.1  [424/232.1; 424/205.1; 424/93.3; 424/277.1; 435/7.23]

25 Claims

1. A recombinant vaccinia virus, comprising a modified thymidine kinase (TK) gene, a modified hemagglutinin (HA) gene, and a modified F3 gene or locus, wherein each of said gene or locus is inactivated, wherein the vaccinia virus is a Lister strain.